Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report
Current landscape of personalized and molecular-driven approach to cancer treatment contributes to a rapid growth of novel biomarkers used for a targeted therapy. Amplification or over-expression of HER2 has been shown to play an important role in the development and progression of some cancers. Rec...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5288 |
| _version_ | 1827961610465968128 |
|---|---|
| author | A. A. Kachmazov L. V. Bolotina A. L. Kornietskaya T. V. Ustinova V. A. Tolstov A. A. Fedenko |
| author_facet | A. A. Kachmazov L. V. Bolotina A. L. Kornietskaya T. V. Ustinova V. A. Tolstov A. A. Fedenko |
| author_sort | A. A. Kachmazov |
| collection | DOAJ |
| description | Current landscape of personalized and molecular-driven approach to cancer treatment contributes to a rapid growth of novel biomarkers used for a targeted therapy. Amplification or over-expression of HER2 has been shown to play an important role in the development and progression of some cancers. Recent studies have shown that over-expression of HER2 is found in up to 5% of colorectal cancers (CRC). These findings led to active research of therapeutic use of HER2-targeted therapy in a subset of patients with metastatic CRC, especially in patients with wild-type RAS, who progressed on anti-EGFR targeted therapy. According to data from several published studies, the rate of objective responses, progression-free and overall survival in this subset of patients matches or exceeds same rates that are achieved while using BRAF-targeted therapies in BRAF-mutated metastatic CRC patients and immunotherapy used in subjects diagnosed with MSI-H tumors. Currently, there is no conclusive data on potential of HER2-targeted therapy in RAS-mutated CRC patients. In this paper, we report a case of durable objective response obtained on trastuzumab therapy in patient with metastatic CRC, mutation in 12th exon of KRAS gene and over-expression of HER2 in 40% of tumor cells, after progression on several lines of chemotherapy and anti-angiogenic targeted therapy. |
| first_indexed | 2024-04-09T16:29:24Z |
| format | Article |
| id | doaj.art-2a91c1c8980c404c978cb42def4df3e3 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:29:24Z |
| publishDate | 2019-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-2a91c1c8980c404c978cb42def4df3e32023-04-23T06:57:10ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-12-0101912613110.21518/2079-701X-2019-19-126-1314808Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case reportA. A. Kachmazov0L. V. Bolotina1A. L. Kornietskaya2T. V. Ustinova3V. A. Tolstov4A. A. Fedenko5Federal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationCurrent landscape of personalized and molecular-driven approach to cancer treatment contributes to a rapid growth of novel biomarkers used for a targeted therapy. Amplification or over-expression of HER2 has been shown to play an important role in the development and progression of some cancers. Recent studies have shown that over-expression of HER2 is found in up to 5% of colorectal cancers (CRC). These findings led to active research of therapeutic use of HER2-targeted therapy in a subset of patients with metastatic CRC, especially in patients with wild-type RAS, who progressed on anti-EGFR targeted therapy. According to data from several published studies, the rate of objective responses, progression-free and overall survival in this subset of patients matches or exceeds same rates that are achieved while using BRAF-targeted therapies in BRAF-mutated metastatic CRC patients and immunotherapy used in subjects diagnosed with MSI-H tumors. Currently, there is no conclusive data on potential of HER2-targeted therapy in RAS-mutated CRC patients. In this paper, we report a case of durable objective response obtained on trastuzumab therapy in patient with metastatic CRC, mutation in 12th exon of KRAS gene and over-expression of HER2 in 40% of tumor cells, after progression on several lines of chemotherapy and anti-angiogenic targeted therapy.https://www.med-sovet.pro/jour/article/view/5288chemotherapytargeted therapyher2trastuzumabcolorectal cancer |
| spellingShingle | A. A. Kachmazov L. V. Bolotina A. L. Kornietskaya T. V. Ustinova V. A. Tolstov A. A. Fedenko Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report Медицинский совет chemotherapy targeted therapy her2 trastuzumab colorectal cancer |
| title | Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report |
| title_full | Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report |
| title_fullStr | Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report |
| title_full_unstemmed | Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report |
| title_short | Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report |
| title_sort | possibilities of therapeutic use of her2 inhibitorsin metastatic colorectal cancer a case report |
| topic | chemotherapy targeted therapy her2 trastuzumab colorectal cancer |
| url | https://www.med-sovet.pro/jour/article/view/5288 |
| work_keys_str_mv | AT aakachmazov possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport AT lvbolotina possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport AT alkornietskaya possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport AT tvustinova possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport AT vatolstov possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport AT aafedenko possibilitiesoftherapeuticuseofher2inhibitorsinmetastaticcolorectalcanceracasereport |